PURPOSE: Bcl-2 and bax are proteins with opposing roles in apoptosis regulation; yet abnormal expression of either has been associated with failure after radiotherapy (RT). In this study we examined bcl-2 and bax expression as predictive markers in men treated with radiotherapy +/- androgen deprivation on Radiation Therapy Oncology Group (RTOG) protocol 86-10. EXPERIMENTAL DESIGN: Suitable archival diagnostic tissue was obtained from 119 (26%) patients for bcl-2 analysis and 104 (23%) patients for bax analysis. Cox proportional hazards multivariate analysis was used to determine the relationship of abnormal bcl-2 and bax expression to the end points of local failure, distant metastasis, cause-specific mortality, and overall mortality. Bcl-2 overexpression was classified as any tumor cell cytoplasmic staining and altered bax expression was classified as greater or lesser cytoplasmic staining intensity of tumor cells as compared with adjacent normal prostate epithelium. RESULTS: The study cohort exhibited bcl-2 overexpression in 26% (n = 30) of cases and abnormal bax expression in 47% (n = 49) of cases. A borderline significant relationship was observed between abnormal bax expression and higher Gleason score (p = 0.08). In univariate and multivariate analyses, there was no statistically significant relationship seen between abnormal bcl-2 or bax expression and outcome. CONCLUSIONS: Abnormal bcl-2 and bax expression were not related to any of the end points tested. The cohort examined was comprised of patients with locally advanced disease and it is possible that these markers may be of greater value in men with earlier-stage prostate cancer.
PURPOSE:Bcl-2 and bax are proteins with opposing roles in apoptosis regulation; yet abnormal expression of either has been associated with failure after radiotherapy (RT). In this study we examined bcl-2 and bax expression as predictive markers in men treated with radiotherapy +/- androgen deprivation on Radiation Therapy Oncology Group (RTOG) protocol 86-10. EXPERIMENTAL DESIGN: Suitable archival diagnostic tissue was obtained from 119 (26%) patients for bcl-2 analysis and 104 (23%) patients for bax analysis. Cox proportional hazards multivariate analysis was used to determine the relationship of abnormal bcl-2 and bax expression to the end points of local failure, distant metastasis, cause-specific mortality, and overall mortality. Bcl-2 overexpression was classified as any tumor cell cytoplasmic staining and altered bax expression was classified as greater or lesser cytoplasmic staining intensity of tumor cells as compared with adjacent normal prostate epithelium. RESULTS: The study cohort exhibited bcl-2 overexpression in 26% (n = 30) of cases and abnormal bax expression in 47% (n = 49) of cases. A borderline significant relationship was observed between abnormal bax expression and higher Gleason score (p = 0.08). In univariate and multivariate analyses, there was no statistically significant relationship seen between abnormal bcl-2 or bax expression and outcome. CONCLUSIONS: Abnormal bcl-2 and bax expression were not related to any of the end points tested. The cohort examined was comprised of patients with locally advanced disease and it is possible that these markers may be of greater value in men with earlier-stage prostate cancer.
Authors: G D Grossfeld; A F Olumi; J A Connolly; K Chew; J Gibney; V Bhargava; F M Waldman; P R Carroll Journal: J Urol Date: 1998-05 Impact factor: 7.450
Authors: D J Grignon; R Caplan; F H Sarkar; C A Lawton; E H Hammond; M V Pilepich; J D Forman; J Mesic; K K Fu; R A Abrams; T F Pajak; W U Shipley; J D Cox Journal: J Natl Cancer Inst Date: 1997-01-15 Impact factor: 13.506
Authors: Tobias Zellweger; Christoph Ninck; Martina Mirlacher; Matthias Annefeld; Andrew G Glass; Thomas C Gasser; Michael J Mihatsch; Edward P Gelmann; Lukas Bubendorf Journal: Prostate Date: 2003-04-01 Impact factor: 4.104
Authors: M Colombel; F Symmans; S Gil; K M O'Toole; D Chopin; M Benson; C A Olsson; S Korsmeyer; R Buttyan Journal: Am J Pathol Date: 1993-08 Impact factor: 4.307
Authors: Rile Li; Kateri Heydon; M Elizabeth Hammond; David J Grignon; Mack Roach; Harvey B Wolkov; Howard M Sandler; William U Shipley; Alan Pollack Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Alan Pollack; Didier Cowen; Patricia Troncoso; Gunar K Zagars; Andrew C von Eschenbach; Marvin L Meistrich; Timothy McDonnell Journal: Cancer Date: 2003-04-01 Impact factor: 6.860
Authors: Alan Pollack; Deukwoo Kwon; Gail Walker; Li Yan Khor; Eric M Horwitz; Mark K Buyyounouski; Radka Stoyanova Journal: J Natl Cancer Inst Date: 2017-02-01 Impact factor: 13.506
Authors: Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H Hammond; Varagur Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Alan Pollack Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: Li-Yan Khor; Kyounghwa Bae; Tahseen Al-Saleem; Elizabeth H Hammond; David J Grignon; William T Sause; Miljenko V Pilepich; Paul P Okunieff; Howard M Sandler; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-01 Impact factor: 7.038
Authors: Min Zhang; Alex Ho; Elizabeth H Hammond; Yoshiyuki Suzuki; R Scott Bermudez; R Jeffrey Lee; Michael Pilepich; William U Shipley; Howard Sandler; Li-Yan Khor; Alan Pollack; Arnab Chakravarti Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-30 Impact factor: 7.038
Authors: P T Tran; R K Hales; J Zeng; K Aziz; T Salih; R P Gajula; S Chettiar; N Gandhi; A T Wild; R Kumar; J M Herman; D Y Song; T L DeWeese Journal: Curr Mol Med Date: 2012-07-01 Impact factor: 2.222
Authors: Yu Li; Hong Ma; Ye Lu; B J Tan; L Xu; Temitope O Lawal; Gail B Mahady; Daniel Liu Journal: Biomed Res Int Date: 2016-02-14 Impact factor: 3.411
Authors: Larry Pan; Seunghee Baek; Pamela R Edmonds; Mack Roach; Harvey Wolkov; Satish Shah; Alan Pollack; M Elizabeth Hammond; Adam P Dicker Journal: Radiat Oncol Date: 2013-04-25 Impact factor: 3.481